Evolus Appoints New Chief Medical Officer
Ticker: EOLS · Form: 8-K · Filed: Apr 3, 2024 · CIK: 1570562
Sentiment: neutral
Topics: executive-appointment, personnel
Related Tickers: RVNC
TL;DR
Evolus names Dr. David Stark, ex-Revance CMO, as its new CMO, effective April 1st.
AI Summary
Evolus, Inc. announced on April 2, 2024, the appointment of Dr. David J. Stark as Chief Medical Officer and Executive Vice President, effective April 1, 2024. Dr. Stark will be responsible for leading the company's clinical development and medical affairs. He previously served as Chief Medical Officer at Revance Therapeutics.
Why It Matters
The appointment of a new Chief Medical Officer is crucial for Evolus as it signals a strategic move to bolster its leadership in clinical development and medical affairs, potentially impacting future product pipelines and regulatory strategies.
Risk Assessment
Risk Level: low — This filing is a routine personnel announcement regarding an executive appointment and does not involve significant financial or operational changes.
Key Players & Entities
- Evolus, Inc. (company) — Registrant
- Dr. David J. Stark (person) — Appointed Chief Medical Officer
- April 2, 2024 (date) — Date of Report
- April 1, 2024 (date) — Effective date of appointment
- Revance Therapeutics (company) — Dr. Stark's former employer
FAQ
Who has been appointed as the new Chief Medical Officer of Evolus, Inc.?
Dr. David J. Stark has been appointed as the new Chief Medical Officer and Executive Vice President of Evolus, Inc.
When was Dr. David J. Stark's appointment effective?
Dr. David J. Stark's appointment was effective April 1, 2024.
What is Dr. David J. Stark's new role at Evolus, Inc.?
Dr. David J. Stark's new role is Chief Medical Officer and Executive Vice President.
What was Dr. David J. Stark's previous position?
Dr. David J. Stark previously served as Chief Medical Officer at Revance Therapeutics.
What is the date of this Form 8-K filing?
The Form 8-K filing is dated April 2, 2024.
Filing Stats: 572 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-04-03 16:29:58
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share EOLS The Nasdaq Stock Market
Filing Documents
- eols-20240402.htm (8-K) — 23KB
- 0001570562-24-000061.txt ( ) — 147KB
- eols-20240402.xsd (EX-101.SCH) — 2KB
- eols-20240402_lab.xml (EX-101.LAB) — 23KB
- eols-20240402_pre.xml (EX-101.PRE) — 13KB
- eols-20240402_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Evolus, Inc. Dated: April 3, 2024 /s/ David Moatazedi David Moatazedi President and Chief Executive Officer